Vaxcyte (PCVX) Common Equity (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Common Equity data on file, last reported at $3.0 billion in Q1 2026.

• On a quarterly basis, Common Equity fell 6.38% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 6.38% decrease from a year earlier, with the FY2025 full-year figure at $2.7 billion, down 18.76% from the prior year.
• Common Equity for Q1 2026 stood at $3.0 billion, up from $2.7 billion in the prior quarter.
• Over the last five years, Common Equity for PCVX reached as high as $3.4 billion in Q3 2024 and fell as low as $359.3 million in Q3 2022.
• Historically, Common Equity has averaged $1.9 billion across 5 years, with a median of $2.0 billion in 2024.
• Across the five-year window, Common Equity jumped 291.1% in 2023 and declined 18.76% in 2025, its largest moves.
• Year by year, Common Equity stood at $953.6 million in 2022, then jumped by 30.08% to $1.2 billion in 2023, then soared by 166.5% to $3.3 billion in 2024, then retreated by 18.76% to $2.7 billion in 2025, then gained by 11.56% to $3.0 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $3.0 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.9 billion in Q3 2025.